FDA approves valve treated to prevent calcification

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

The FDA approved a bioprosthetic heart valve that is treated to improve durability.

The Italian company Sorin Group announced that it received FDA approval for its Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment. The treatment extracts phospholipids from pericardial tissue. Phospholipids have been linked to the calcification process of bioprotheses, which affects durability. In animal models, the treatment process reduced calcium uptake compared with a control.

Mitroflow with Phospholipid Reduction Treatment received CE mark on July 28, 2011.

Candace Stuart, Contributor

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind
Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.